The Board of Directors serves as an advisory and oversight board to the American Physician Scientists Association and the Executive Council. The board is made of physician-scientist stakeholders and leaders and of former/current members of the APSA Executive Council. Together this group of individuals not only maintain and guide the long term vision of the organization but they also retain the institutional memory for the organization.
Dr. Ivayla (Eve) Geneva is an MD-PhD candidate at SUNY Upstate Medical University, having previously graduated Magna Cum Laude from Whitman College with a BS in Biophysics, Biochemistry, and Molecular Biology. During her undergraduate education, Ms. Geneva earned both the Abshire Research Award and the Perry Research Grant, while garnering awards for outstanding performance in physical chemistry and an international student scholarship. Within APSA, Ms. Geneva has served as Treasurer, where she oversaw organizational funding and financial policy, as Institutional Representative for her medical school, and as President in 2011-2012. Ms. Geneva is currently Chair of the APSA Board of Directors. On the local level, she is currently holding the positions of Student Ambassador to the President at SUNY Upstate Medical University and President of the Upstate Ophthalmology Club. Ms. Geneva has also served as a member of Upstate's Strategic Plan Implementation Committee for Research.
Dr. Jaimo Ahn, MD, PhD is an Assistant Professor of orthopaedic surgery and Co-director of orthopaedic trauma at the Perleman School of Medicine at the University of Pennsylvania. He completed a fellowship in Orthopaedic Traumatology at the Hospital for Special Surgery, Weill Cornell Medical College (2008-2009). He did his internship and residency in orthopaedic surgery at the University of Pennsylvania (2003-2008) where he also received his MD-PhD in Cell & Molecular Biology (1995-2003). Dr. Ahn received his undergraduate degree in Biological Sciences from Stanford University. In addition to studying the education and development of physician-scientists, he co-manages a laboratory with a focus on molecular modulation of bone formation and healing and a clinical research program with a focus on prospective evaluation of orthopaedic trauma outcomes. He is active in medical education, serving as Director of the Penn Med orthopaedic clerkship, Assistant Director of the orthopaedic residency program and as a member of the USMLE Step II question development committee, and enjoys reviewing for journals as varied as JAMA and the Journal of Bone and Joint Surgery. Outside of academics, he especially enjoys food, wine, travel and exercise with his wife. Dr. Ahn became a member of the APSA Board of Directors in April of 2007 and served as Chair in 2012-2013.
Dr. Evan Noch is a first-year Neurology resident at Weill-Cornell Medical Center-New York Presbyterian Hospital in New York City in a research-track residency program with protected research time during residency and guaranteed fellowship funding for one year after completing the program. He obtained his MD and PhD degrees from Temple University School of Medicine, where he studied the role of oncogenes in the regulation of oxygen and glucose metabolism in the pathogenesis of glioblastoma and medulloblastoma. Evan received his BS in Neuroscience from New York University in 2006. Since joining Temple in 2006, Evan has served as co-chair of various student organizations, including the Student Interest Group in Neurology and the Jewish Student Union. In addition, during his PhD training, Evan presented abstracts at several meetings, including the 10th Symposium of the International Society for Neurovirology in Milan, Italy, where he received the Volker ter Meulen Investigator-in-Training Award. Upon completion of his PhD, Evan received the Florence Gloria Freedman Award for Cancer Research. This past year, Evan received the American Academy of Neurology 2013 Medical Student Prize for Excellence in Neurology. Evan has received travel awards to a variety of meetings, including those of the International Society for Neurovirology, the American Academy of Neurology, as well as the Central Society for Clinical and Translational Research and the Midwestern Section of the American Federation for Medical Research. Evan has been a member of APSA for 5 years, serving on the PR Committee and then the Chair of the PR Committee and as the APSA President-Elect last year. Evan is the current President of APSA. Evan is passionate about APSA and its mission in promoting the goals of physician-scientists, and he hopes to improve the visibility of APSA over this year and expand this organization through its meetings, membership, and website and social media activities.
Mr. Michael Guo is currently a second-year graduate student (G2) in the Harvard program in Biological and Biomedical Sciences. He is also an MD/PhD student at the University of Florida, but is completing his PhD studies at Harvard. Michael attended the University of Michigan for his undergraduate degree, where he graduated with high distinction, obtaining a BBA in Business Administration and a BS in Cellular and Molecular Biology. His current research focuses on identifying genetic variants underlying both monogenic and complex human traits and developing functional approaches to validate and study these variants. Mr. Guo has previously served as the chair of the finance committee for APSA, as well as president of his local chapter. He currently serves as the President-Elect of APSA.
Dr. Hans Arora, M.D. Ph.D. is urology resident physician at the Cleveland Clinic Foundation Glickman Urological and Kidney Institute. He is a graduate of the Medical Scientist Training Program (MSTP) at the Northwestern University Feinberg School of Medicine, graduating Magna Cum Laude. He received his B.S. with Honors in Chemical Engineering from Pennsylvania State University, and completed his Ph.D. in the laboratory of Dr. Gayle Woloschak in the Department of Radiation Oncology. His dissertation research involved the use of titanium dioxide nanoparticles to overcome cancer chemotherapy drug resistance in ovarian cancer, the number one cause of gynecologic cancer death in women. Specifically he studied the effects of titanium dioxide-doxorubicin nanoconjugates, and their effects on the uptake, localization, and cytotoxicity as compared to free doxorubicin in a drug-resistance ovarian carcinoma model. Interestingly, he found that both free nanoparticles and nanoconjugates increased the uptake of transferrin, a marker for clathrin-mediated endocytosis. His prior research experiences include internships at the National Institutes of Health, the Armed Forces Radiobiology Research Institute, and Pennsylvania State University. His research has been presented at numerous national and international conferences, including the American Society for Radiation Oncology, the American Association for Cancer Research, and the Gordon Conference on Radiation Oncology, and has been supported by national and local research grants from the American Medical Association Foundation, the National Institutes of Health Center for Cancer Nanotechnology Excellence, and the Northwestern University Clinical and Translational Sciences Institute (NUCATS).
Hans continues to be active in the medical community throughout his time as a medical students and resident physician at the national, state, and local levels. He has served as National Chair of the Medical Student Section of the American Medical Association; Physician Advisory Board member of Building a Healthier Chicago; as well as a Trustee of the Illinois State Medical Society, Chicago Medical Society, and the American Physician Scientists Association. For his academic and professional accomplishments, he has been awarded the American Medical Association Foundation Excellence in Leadership Award, the Chicago Medical Society’s inaugural Outstanding Student Award, the Heller Award for Excellence in Clinical Medicine, and was inducted into the Alpha Omega Alpha Honor Medical Society. His continuing research interests involve the molecular mechanisms of disease in urologic oncology.
Dr. Jill Baren is Chair of the Department of Emergency Medicine and Chief of Emergency Services at the University of Pennsylvania Health System, and Professor of Emergency Medicine and Pediatrics, Perelman School of Medicine at the University of Pennsylvania.
Dr. Baren recently served as President of the Society for Academic Emergency Medicine (www.saem.org), the largest organization in the world solely dedicated to education and research in the specialty. Dr. Baren has lectured extensively, both nationally and internationally. She has published over 80 peer-reviewed articles, editorials and book chapters and is the senior editor of an evidence-based, clinically focused textbook entitled, "Pediatric Emergency Medicine.” Dr. Baren completed a Master of Bioethics degree in the Department of Medical Ethics at the University of Pennsylvania in 2004 and now serves as a faculty in the graduate degree program. She is a nationally recognized expert in the application of the federal regulations for the use of waiver of consent and the emergency exception from informed consent in clinical trials. Dr. Baren’s current research focuses on informed consent and the logistics and special protections of research subjects involved in clinical trials using emergency exception from informed consent. She is the principal investigator of the Greater Philadelphia Southern New Jersey Neurological Emergencies Treatment Trial Network, a consortium of 14 hospitals involving a research team of over 40 individuals.
Dr. David Braun, MD, PhD is the former President of APSA. He is currently a resident physician in the Department of Medicine at the Brigham and Women's Hospital and a Clinical Fellow in Medicine at Harvard Medical School. He received his MD with a Distinction in Medical Education from the Icahn School of Medicine at Mount Sinai, where he was the first Sanfurd Bluestein, MD Scholar, and from which he was received the Dr. Barry Coller Award for Excellence in Clinical Medicine. He received his PhD from the Joint Program in Computational Biology at the Courant Insitute of New York University. He graduated Magna Cum Laude from Princeton University with an A.B. in Molecular Biology, and Certificates in Engineering Biology and Computer Science. In addition to his work with APSA, Dr. Braun has served as Co-President of the Mount Sinai Chapter of Physicians for Human Rights, and as the Chief Clinic Manager of the East Harlem Health Outreach Partnership, a student-run clinic that provides free comprehensive medical care to the uninsured. In 2008, Dr. Braun was award the Excellence in Medicine Leadership Award by the American Medical Association Foundation, and the Outstanding Leadership Award by the Mount Sinai School of Medicine. Within APSA, Dr. Braun has served as President, as Chair of the Membership Committee, and as the Institutional Representative for Mount Sinai. In 2007, Dr. Braun initiated and organized the APSA New York Physician Scientists Symposium, which has since become an annual event in the Northeast that draws hundreds of trainees from dozens of institutions each year. His central goal is to help ensure that the enormous promise of translational medicine will be effectively delivered to the community and society at large.
Dr. Oscar Cuzzani, MD, DSc is a physician-scientist who specializes in ophthalmology (retina, immunology and glaucoma) with experience in phase 2-3 clinical trials and pharmacovigilance. He has seven years of experience in eye biomechanics with special emphasis in the application of finite element analysis, computational mathematics, and artificial intelligence to develop a virtual biomechanical and optical model of the eye with applications to surgery and soft testing of new compounds/delivery systems in glaucoma. His experience also extends into clinical research in AMD, uveitis (where he evaluated the link between light exposure and breakdown of the blood-ocular barrier with the aim to modulate inflammatory cascades via filtering specific spectra), and anterior segment surgery. From 2007 to 2010, he served as the Director of Clinical Research in the areas of retina and glaucoma and in pharmacovigilance at QLT Inc. From October 2010 to the present, he has served as the Associate Medical Director at Abbott Labs, Abbott Park, IL. Since July 2013 he is Director Global Clinical Development at Allergan Inc, Irvine, CA.
Ophthalmology- Retina, immunology, glaucoma. Start-up in medical devices. Clinicaltrials phases 2-3. Pharmacovigilance. Multidisciplinary teams: computational mathematics,engineering, biomaterials, biosensors, laser interferometry, artificial intelligence, evolutionarymodeling. Scientific assessment of emerging drugs for ophthalmology. Ophthalmic, immunologydrug development.
Dr. Shwayta Kukreti, MD, PhD is resident who will be training in Radiology at UCLA. Currently she is pursuing her preliminary medicine year at the University of Illinois at Urbana-Champaign. In 2011 she completed the Medical Scholars MD/PhD Program at the University of Illinois-Urbana, Champaign. She received her PhD in Biophysics and Computational Biology in 2007 working at the Laboratory for Fluorescence Dynamics in collaboration with the Beckman Laser Institute and Medical Clinic at the University of California-Irvine. Dr. Kukreti's research focus is in biomedical devices, which has led to a patent. More specifically, using lasers she is interested in developing methods for breast imaging and analysis using optical spectroscopy. Dr. Kukreti graduated Bronze Tablet, Summa Cum Laude, with Bachelors of Sciences degrees in Honors Biology and Biochemistry from the University of Illinois-Urbana, Champaign in 2003. She serves a mentor for undergraduate students interested in math, science and engineering. Dr. Kukreti joined APSA as Vice President from 2007-2008. Currently she serves on the Nominations Committee of the APSA Board of Directors.
Dr. Moshe Levi MD obtained his degrees in Chemical Engineeringfrom Northwestern University (BS) and Stanford University (MS) and his medical degree from Albert Einstein College of Medicine. He completed his internship and residency training in internal medicine at Cornell Medical College and his fellowship training at the University of Colorado. He was in the faculty in the University of Texas Southwestern Medical Center from 1984-2002 and since 2002 at the University of Colorado where he is currently Professor of Medicine & Physiology and Biophysics & Bioengineering. He is a practicing Nephrologist and he also leads an active research lab investigating 1) the regulation of renal and intestinal phosphate transport, 2) obesity, diabetes and aging related kidney disease, and 3) atherosclerosis and vascular calcification.
Dr. David Markovitz is a Professor of Internal Medicine in the Division of Infectious Diseaseswho also has appointments in the programs in Cellular and Molecular Biology, CancerBiology, and Immunology. His laboratory focuses on understanding how human cellularfactors control the replication of retroviruses such as HIV. These studies are performed bothto understand the biology of retroviruses and to develop possible therapies for these importanthuman pathogens, as well as to exploit the viruses as a mechanism for understanding humancellular biology. Current interests in the laboratory focus on four areas: First, the laboratoryis studying endogenous human retroviruses, retroviruses that have insinuated themselves intothe human genome over the course of millions of years and now make up fully eight percentof our genomes. The Markovitz laboratory is studying whether, contrary to existing dogma,these viruses can still replicate, as well as investigating the role of these viruses in AIDS, cancer,and other diseases. A second project deals with the DEK protein, which is involved in cancercausation and the pathogenesis of juvenile arthritis. Third, the laboratory is working on themolecular engineering of a banana lectin that could be part of a vaginal microbicide used toprevent the sexual spread of HIV and perhaps in the treatment of viral infections. Lastly, theMarkovitz research group is studying the role of the intermediate filament protein vimentin ininflammation. These studies are carried out in conjunction with a wide variety of Ph.D. andM.D. trainees, as well as in close collaboration with a number of faculty members from diversedepartments at the University of Michigan and other institutions. Dr. Markovitz's work has beenrecognized by his election to the two principal honorary societies for academic Internal Medicinephysicians, the American Society for Clinical Investigation and the Association of AmericanPhysicians, and he is the Chair of the Research Committee of the Infectious Diseases Society ofAmerica.
Dr. Juanita L. Merchant, MD, PhD, is an H. Marvin Pollard Professor of Gastrointestinal Sciences in the Departments of Internal Medicine (Gastroenterology) and Molecular and Integrative Physiology. She received her BS from Stanford University and MD, Ph.D. from Yale University. Her PhD degree is in Cell Biology. She completed internship and residency at MGH, Boston and a her postdoctoral fellowship in Gastroenterology at MGH. She completed a Clinical Fellowship in GI at UCLA before being recruited to the University of Michigan. She serves on a number of boards and is an associate director of the UM MSTP. Dr. Merchant's research focuses on the molecular mechanisms underlying normal and cancerous epithelial cell growth in the luminal gastrointestinal tract. Her recent studies use transgenic animal and cell culture models to dissect the pathways through which bacterial colonization in the stomach leads to chronic inflammation, metaplasia then cancer. Ongoing projects in her laboratory include the role of sonic hedgehog in chronic gastritis and acid secretion; the role of the nuclear protein menin in the genesis of gastrinomas and the role of the transcription factor ZBP-89 in enterochromaffin cell biology, function and colon cancer.
Dr. M. Kerry O'Banion, MD, PhD is Professor and Associate Chair in the Department of Neurobiology and Anatomy at the University of Rochester School of Medicine & Dentistry. He received his MD-PhD from the University of Illinois at Urbana-Champaign Medical Scholars Program in 1987 and now leads a laboratory focused on understanding the role of neuroinflammation in acute and degenerative brain disease. Dr. O'Banion directs the Medical Scientist Training Program at the University of Rochester and served as Chair of the MD-PhD Section of the Association of American Medical Colleges' Graduate Research, Education, and Training (GREAT) Group in 2009-2010. Dr. O'Banion has been a member of the APSA Board of Directors since March of 2006 and was an advisor to APSA as early as January of 2004 during APSA's initial inception. Dr. O'Banion serves on the Nominations Committee of the APSA Board of Directors and is principal investigator of an R13 grant from the National Cancer Institute that supports APSA's National Meeting.
Dr. Eric Schauberger is a DO-PhD candidate in his MS4 year in the Michigan State University Physician Scientist Training Program. He received his PhD in Genetics from Michigan State in 2011. His dissertation title was "The identification of ATPAF1 as a novel asthma susceptibility gene and the characterization of functional regulatory variants".He received his BS in Genetics from Iowa State University in 2003. He was awarded the Senior Leadership award by Iowa State. He has been actively involved at his college and APSA leadership including serving as Chair of the Policy committee and member of the Executive Council in 2009-10. He is currently completing his clerkships at MetroHealth Hospital in Grand Rapids, MI and will graduate in May 2012. Eric and his wife, who is a small animal veterinarian, have two rescued greyhounds and two cats. He joined the APSA Board of Directors in July of 2011.
Dr. Michael Zasloff, MD, PhD, a leader in innate immunity, is a Professor of Surgery and Pediatrics at Georgetown University School of Medicine. Dr. Zasloff received his MD, PhD degrees from the New York University Medical Scientist Training Program. He completed his residency training in pediatrics at the Boston Children's Hospital and his post-doctoral training at the NIH in molecular genetics. In 1981, Dr. Zasloff was named Chief of the Human Genetics Branch of the National Institutes of Child Health and Human Development. In 1989, he became the Charles E.H. Upham Professor of Pediatrics and Genetics at the University of Pennsylvania School of Medicine and Chief of the Division of Human Genetics of the Children's Hospital of Philadelphia. He founded Magainin Pharmaceuticals, Inc. in 1988 and served as its Executive Vice President and President of the Magainin Research Institute in 1992. Dr. Zasloff became Vice Chairman of its Board of Directors during 1996-2000. He went on to serve as Dean of Research and Translational Science at the Georgetown University Medical Center, and primarily responsible for the overall management of Georgetown's biomedical research and its translation from the laboratory to patient care. Dr. Zasloff joins the APSA Board of Directors in July of 2009.